Fabio Turco , Consuelo Buttigliero , Marco Donatello Delcuratolo , Silke Gillessen , Ursula Maria Vogl , Thomas Zilli , Nicola Fossati , Andrea Gallina , Giovanni Farinea , Rosario Francesco Di Stefano , Mariangela Calabrese , Isabella Saporita , Veronica Crespi , Stefano Poletto , Erica Palesandro , Massimo Di Maio , Giorgio Vittorio Scagliotti , Marcello Tucci
{"title":"Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives","authors":"Fabio Turco , Consuelo Buttigliero , Marco Donatello Delcuratolo , Silke Gillessen , Ursula Maria Vogl , Thomas Zilli , Nicola Fossati , Andrea Gallina , Giovanni Farinea , Rosario Francesco Di Stefano , Mariangela Calabrese , Isabella Saporita , Veronica Crespi , Stefano Poletto , Erica Palesandro , Massimo Di Maio , Giorgio Vittorio Scagliotti , Marcello Tucci","doi":"10.1016/j.clgc.2024.102138","DOIUrl":null,"url":null,"abstract":"<div><p>Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
